Table 1.
POPG inhibits infection by clinical isolates and recombinant variants of RSV.
| RSV Strain | Titer (pfu/ml) | Plaques w/ POPG | Plaques w/ POPC |
|---|---|---|---|
| JX069798.1 | 8.3±4.7(E+05) | 0 | 3.0±3.5(E+05) |
| JX069803.1 | 4.8±0.4(E+06) | 0 | 0.5±0.1(E+06) |
| JX069801.1 | 1.1±0.2(E+07) | 2.6±3.6(E+02) | 0.4±0.2(E+07) |
| JX069800.1 | 1.1±0.1(E+07) | 3.0±4.2(E+02) | 0.5±0.2(E+07) |
| JX069799.1 | 5.3±0.5(E+04) | 0 | 0.7±0.3(E+04) |
| rA2-A2 F | 1.2±0.4(E+07) | 0.5±0.01(E+02) | 0.8±0.02(E+07) |
| rA2- line19F | 3.0±0.7(E+06) | 0 | 3.0±0.2(E+06) |
| rA2 Long F | 6.2±0.2(E+06) | 0 | 1.6±0.6(E+06) |
| wtRSV A2 | 2.7±1.1(E+07) | 0 | 1.3±0.3(E+07) |
We determined the antiviral efficacy of POPG against five clinical isolates of RSV (designated by GenBank accession numbers), and recombinant strains of RSV (rA2-A2F, rA2–19F, and rA2 Long F) in comparison to RSV-A2.12 The titer of each strain is shown as PFU/ml, and the efficacies of POPG and POPC (200μg/ml) on each strain are stated as the viral titers by plaque assays. Data are shown as means ± SD from two independent experiments.